Immunohistochemical Study of IDH1, p53, and Ki67 in Gliomas at a Tertiary Care Centre in India
DOI:
https://doi.org/10.21276/apalm.3455Keywords:
IDH1, p53, Ki67, gliomasAbstract
Background: Gliomas are the most common primary CNS tumor, accounting for 81% of all malignant intracranial tumors. The incidence rate of gliomas varies considerably according to sex, race, and nationality. The use of biomarkers such as IDH1/2 and MDM2 status is becoming increasingly common in the West. Most of the information regarding these molecular alterations in gliomas is derived from Western literature. Minimal data is available involving these molecules in glial tumors among the Indian population. This study will help estimate the frequency of these molecular alterations in gliomas in the Indian population.
Materials and Methods: In this prospective study, 60 histopathologically proven cases of gliomas were taken. Representative sections were taken from the tumor area, wax blocks were prepared, and IHC (IDH1, p53, Ki67) was performed.
Results: Out of 60 cases, there were 35 (58.3%) males and 25 (41.7%) females. The maximum number of cases was observed in the 6th decade. Glioblastoma multiforme was the most common histological subtype with 23 cases (38.3%), followed by Diffuse Astrocytoma with 16 cases (26.7%). A correlation between various histological subtypes and the grade of glial tumors with IDH1 immunoexpression was found to be highly significant [p<0.001]. A correlation between various histological subtypes and the grade of glial tumors with the Ki67 score was found to be highly significant [p<0.001]. A correlation between various histological subtypes and p53/IDH1 expression, as well as various histological grades and p53/IDH1 expression, was found to be significant [p=0.006,p<0.001].
Conclusion: Our study showed a statistically significant correlation between various histological subtypes and grades of gliomas with p53/IDH1.
References
1. Ostrom TQ, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: “a state of the science” review. Neuro Oncol. 2014;16(7):896–913.
2. Argyriou AA, Antonacopoulou A, Iconomou G, Kalofonos HP. Treatment options for malignant gliomas, emphasising towards new molecularly targeted therapies. Cancer Treat Rev. 2009;69(3):199–210.
3. Montgomery RM, Queioz LDS, Rogerio F. EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation. Arq Neuropsiquiatr. 2015;73(7):561–8.
4. Jackson P, Blythe D. Immunohistochemical techniques. In: Bancroft JD, Gamble M, editors. Theory and practice of histological techniques. 7th ed. New York: Churchill Livingstone; 2012. p. 381–426.
5. Biomedical Waste Management (Amendment) Rules 2018. New Delhi: Gazette of India, Extraordinary, Part II, Section 3, Subsection (I); 2018 Mar 16 [cited 2024 Dec 31]. Available from: http://www.egazette.nic.in/WriteReadData/2018/183847.pdf
6. Arshad H, Ahmad Z, Hasan SH. Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pac J Cancer Prev. 2010;11(6):1637–40.
7. Saeed MS. IDH1 mutation in gliomas in Mosul city - Iraq. Open Access Maced J Med Sci. 2015;3(2):250–5.
8. Chaurasia A, Park SH, Seo JW, Park CK. Immunohistochemical analysis of ATRX, IDH1 and p53 in glioblastoma and their correlation with patient survival. J Korean Med Sci. 2016;31(8):1208–14.
9. Senhaji N, Louati S, Chbani L, Bardai SE, Mikou K, Maaroufi M, et al. Prevalence of IDH1/2 mutations in different subtypes of glioma in the north east population of Morocco. Asian Pac J Cancer Prev. 2016;17(5):2649–53.
10. Mishra S, Rathi KR, Shelly D, Bhardwaj R. Immunohistochemical expression of IDH1R132H in astrocytic tumors and its association with histopathologic grade, Tp53 and EGFR protein expression. Ann Pathol Lab Med. 2017;4(5):1–8.
11. Shaban ZM, Al-Aubaidy SR, Hameedi AD. IDH1 mutation in gliomas in Baghdad by immunohistochemical study. J Genet Genomics. 2018;6(1):1–7.
12. Chatterjee D, Radotra BD, Kumar N, Vashishta RK, Gupta SK. IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population. Surg Neurol Int. 2018;9:1–17.
13. Jaiswal S, Chaudhary N, Prasad P, Khatri D, Das KK, Mehrotra A, et al. Expression of Isocitrate Dehydrogenase-1 (IDH1) mutant proteins in gliomas. Tech Neurosurg Neurol. 2018;1(3):1–6.
14. Mohammad W, Al-Nuaimy H, Al-Nuaimy W. p53 expression in glioma: an immunohistochemical study. Arab Board Med J. 2013;14(3):1–11.
15. Nayak A, Ralte AM, Sharma MC, Singh VP, Mahapatra AK, Mehta VS, et al. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Neurol India. 2004;52(2):228–32.
16. Hu WM, Wang F, Xi SY, Zhang X, Lai JP, Wu HY, et al. Practice of the new integrated molecular diagnostics in gliomas: experiences and new findings in a single Chinese center. J Cancer. 2020;11(6):1371–82.
17. Phatak P, Selvi SK, Divya T, Hegde AS, Hegde S, Somasundaram K, et al. Alterations in tumour suppressor gene p53 in human gliomas from Indian patients. J Biosci. 2002;27(7):673–8.
18. Belghali MY, Rais H, Ba-M’hammed S, Hazmiri FZ, Khoudri NE, Fakhri A, et al. Glial fibrillary acidic protein, CD34, Ki-67 and p53 immunohistochemistry expression study to estimate the concordance between the morphology and the awarded grades of the brain gliomas. Clin Cancer Investig J. 2017;6(1):44–50.
19. Ban Bolly HM, Faried A, Hermanto Y, Lubis BP, Tjahjono FP, Hernowo BS, et al. Analysis of mutant Isocitrate Dehydrogenase 1 immunoexpression, Ki-67 and Programmed Death Ligand 1 in diffuse astrocytic tumours: study of single center in Bandung, Indonesia. J Korean Neurosurg Soc. 2021;64(1):100–9.
20. Verma K, Negi SR, Garhwal S. To study histopathological features, GFAP staining and Ki67/MIB-1 labelling index in diagnoses and histological grading of gliomas. Indian J Forensic Community Med. 2021;8(2):115–9.
21. Sun J, Li DM, Huang J, Liu J, Sun B, Fu DL, et al. The correlation between the expression of ADAM17, EGFR and Ki-67 in malignant gliomas. Eur Rev Med Pharmacol Sci. 2017;21:4595–9.
22. Louis DN, Perry A, Reifenberger G, Deimling AV, Branger DF, Cavenee WK, et al. The 2016 World Health Organisation classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.
23. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry. 1995;59:413–9.
24. Sun J, Li DM, Huang J, Liu J, Sun B, Fu DL, et al. The correlation between the expression of ADAM17, EGFR and Ki-67 in malignant gliomas. Eur Rev Med Pharmacol Sci. 2017;21:4595–9.
25. Qu DW, Xu HS, Han J, Wang YL, Ouyang CJ. Expression of Cyclin D1 and Ki-67 proteins in gliomas and its clinical significance. Eur Rev Med Pharmacol Sci. 2014;18:516–9.
26. Skjulsvik AJ, Mork JN, Torp MO, Torp SH. Ki-67/MIB-1 immunostaining in a cohort of human gliomas. Int J Clin Exp Pathol. 2014;7(12):8905–10.
27. Thotakura M, Tirumalasetti N, Krishna R. Role of Ki-67 labelling index as an adjunct to the histopathological diagnosis and grading of astrocytomas. J Can Res Ther. 2014;10(3):641–5.
28. Hu X, Miao W, Zou Y, Zhang W, Zhang Y, Liu H. Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine – DNA methyltransferase in human gliomas. Oncol Lett. 2013;6(1):130–4.
29. Theresia E, Maluaeka RG, Pranacipta S, Kameswari B, Dananjoyo K, Asmedi, et al. Association between Ki-67 labelling index and histopathological grading of glioma in Indonesian population. Asian Pac J Cancer Prev. 2020;21(4):1063–8.
30. Singh A, Bhardwaj A, Kaushik S, Kishore S, Acharya S. Role of immunohistochemical markers p53 and Ki-67 in grading of glial tumors: a prospective study. J Clin Diagn Res. 2021;15(4):13–7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sujata Kumari, Monika Gupta, Shivani Singhal, Arsha Narayanan, Aakanksha Rawat, Sunita Singh
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).